Tirzepatide Once Weekly for the Treatment of Obesity
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Many patients treated with GLP-1RAs achieve clinically meaningful weight loss while simultaneously demonstrating improvements in cardiometabolic health.45,46”
From Receipt of Glucagon-Like Peptide-1 Receptor Agonists Among Rural Patients with Obstructive Sleep Apnea and Excess Weight (2026) · cites this paper as [46]
In the citing paper
“with two articles presenting LM outcomes in only a subset of participants from the parent trial (6, 7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Indeed, clinical trials demonstrate substantial weight loss achievable with GLP1Ra-based therapy, ranging from 12-15% over a one-year period for semaglutide (6), to weight losses rivaling what is seen with bariatric surgery for tirzepatide (7).”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“Across body weight and composition outcomes, the greatest magnitude of weight loss was observed in the SURMOUNT (7) and STEP (6) trials, respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
In the citing paper
“However, the magnitude of the treatment effect on total body mass was nearly two times greater in trials using GLP1Ra-based therapies at dosages indicated primarily for chronic weight management (6, 7, 18, 21, 24) as compared to trials using dosages indicated primarily for diabetes management (17, 19, 20, 22): −10.2 kg (−16.3, −3.9) versus −5.5 kg (−8.7, −2.1), respectively.”
From G LP1Ra ‐based therapies and DXA ‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials (2025) · cites this paper as [7]
174 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Self-citationObesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Di Angelantonio, E., Bhupathiraju, S. N., Wormser, D., Gao, P., Kaptoge, S., de Gonzalez, A. B., Cairns, B. J., Huxley, R., Jackson, C. L., Joshy, G., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30175-1 · Cited by 2,821
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s002 · Cited by 2,697
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Self-citationGarvey, W. T., Mechanick, J. I., Brett, E. M., Garber, A. J., Hurley, D. L., Jastreboff, A. M., Nadolsky, K., Pessah-Pollack, R., & Plodkowski, R. (2016) · Endocrine Practice · doi:10.4158/ep161365.gl · Cited by 1,914
Self-citationObesity in adults: a clinical practice guideline
Wharton, S., Lau, D. C. W., Vallis, M., Sharma, A. M., Biertho, L., Campbell-Scherer, D., Adamo, K., Alberga, A., Bell, R., Boulé, N., et al. (2020) · Canadian Medical Association Journal · doi:10.1503/cmaj.191707 · Cited by 1,506
Self-citationRubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · JAMA · doi:10.1001/jama.2021.3224 · Cited by 1,444
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Cited by
Items 2,801–2,900 of 3,704
Industrializable Synthesis of Fmoc-Ala-Thr-OH Pseudodipeptide as a Key Intermediate of Peptide Drugs
Li, X., Han, G., Yue, L.-R., et al. (2025) · Synthesis · doi:10.1055/a-2602-4547
Malmborg, M., El‐Chouli, M., Andersen, C. F., et al. (2025) · medRxiv · doi:10.1101/2025.05.05.25327040
The Heated Race Against MASH: Will the Scope, Scalpel, or Medication Prevail?
Samala, N. R., & Al‐Haddad, M. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.02.023
Wird es doch eine medikamentöse Therapie der OSA geben?
Fietze, I. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01902-8
Stute, P. (2025) · Springer eBooks · doi:10.1007/978-3-662-70494-3_4
ANMCO position paper: diagnosis and treatment of heart failure with preserved systolic function
Iacovoni, A., Navazio, A., Luca, L. D., Gori, M., Corda, M., Milli, M., Iacoviello, M., Lenarda, A. D., Tano, G. D., Marini, M., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suaf070
GLP-1 agonists and cardiovascular endpoints in obesity without diabetes
Verlaan, J. P. L. (2025) · Geneesmiddelenbulletin · doi:10.35351/gebu.nl.2025.2.6
Multidisciplinary Care in Body Contouring: An Integrative Approach to Enhancing Outcomes
Dinis, J., Otero, S. P., Quirarte, D. M., Owens, W. R., & Winocour, S. J. (2025) · Seminars in Plastic Surgery · doi:10.1055/s-0045-1807724
Recent advances in the pharmacological treatment of obesity
Nam, G. E. (2025) · Journal of Korean Medical Association · doi:10.5124/jkma.25.0058 · Cited by 1
Tirzepatide for weight reduction in people without diabetes
BMJ Publishing Group Ltd (2025) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2025.000018
Arora, G., Via, M. A., & Mechanick, J. I. (2025) · Springer eBooks · doi:10.1007/978-3-031-77690-8_63-1
Retnakaran, R. R., Pu, J., Hanley, A. J., & Zinman, B. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16513
Traitement pharmacologique des obésités complexes d’origine génétique
Faccioli, N., Dubern, B., Clément, K., & Poitou, C. (2025) · EMC - Endocrinologie - Nutrition · doi:10.1016/s1155-1941(24)48025-6
Gewichtsreduktion mit Inkretinmimetika – Chancen und Risiken
Zech, T., Kirchweger, B., & Fürst, R. (2025) · Die Innere Medizin · doi:10.1007/s00108-025-01918-0
Medical Management of Obesity and Guidelines for Metabolic and Bariatric Surgery
Vishakha, J., & Lohit, K. (2025) · Springer eBooks · doi:10.1007/978-981-96-5099-6_2
Pediatric Obesity Pharmacotherapy
Speakman, A., Ali-Geiger, F., & Mouzaki, M. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.05.001
Ambulatory BP and Weight Reduction as Predictors of GLP-1RA CV BenefitPreprint
Renna, N. F., Ramirez, E. I., Arrupe, M. F., & Ramirez, J. (2025) · medRxiv · doi:10.1101/2025.06.12.25329536
Biopharma Evaluation of Anti-Obesity Vaccines in Global Trials by Dr. Slim™Preprint
Ghalamghash, R. (2025) · Preprints.org · doi:10.20944/preprints202506.0907.v1
The need to address the risk of osteosarcopenia induced by tirzepatide therapy
Mattia, G. D., & Mazzantini, M. (2025) · Clinical and Experimental Rheumatology · doi:10.55563/clinexprheumatol/el8zor
Leitlinienkonforme Adipositastherapie: Medikamentöse Therapie und Langzeitperspektiven
Engeli, S. (2025) · CardioVasc · doi:10.1007/s15027-025-3784-3
Sind GLP-1-Rezeptor-Agonisten und SGLT2-Inhibitoren auch im höheren Lebensalter geeignet?
Stüdemann, S., & Engeli, S. (2025) · Diabetes aktuell · doi:10.1055/a-2588-6338
Slater, N. A. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_12
Management of Comorbid Conditions
Phillips, C. M. (2025) · Springer eBooks · doi:10.1007/978-3-031-88835-9_13
Analysis of the different approaches effectiveness to the treatment of patients with obesity
Khamzaeva, M. S.-U., Filonova, K. E., Gorina, N. A., Oorzhak, C. O., & Ivanova, V. V. (2025) · Russian Journal of Preventive Medicine · doi:10.17116/profmed202528061120
Chen, A. S., Brunetto, W. L., Canavan, M., Lipska, K. J., Richey, E. A., Wilson, M. S., Zarro, J., & Ross, J. S. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09691-4 · Cited by 1
Mixed-Chirality Prohibitin Peptide: D-(RLARLAR)2 Enhances Stability and In Vivo Effects on Obesity
Chan, L. Y., Weger, B. D., Weger, M., Du, J., Lawrence, N., Cardoso, M. H. E. S., de Rezende, S. B., Muller, J. D. A. I., Yap, K., Tse, B. W.-C., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c05536 · Cited by 1
Prosecký, R., & Karoliová, K. H. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.041
Übergewicht und Frauengesundheit: Gynäkologische Erkrankungen im Zusammenhang mit Adipositas
Franz, M. (2025) · gynäkologie + geburtshilfe · doi:10.1007/s15013-025-6117-9
Faut-il faire maigrir les patients ayant une insuffisance respiratoire chronique et une obésité ?
Borel, A., Suzeau, P., & Borel, J. (2025) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2025.06.004
High-risk populations should be screened for MS: No
Lebrun‐Frénay, C., & Okuda, D. T. (2025) · Multiple Sclerosis Journal · doi:10.1177/13524585251353025
Neue Therapien bei Adipositas im Kindesalter
Gomahr, J., & Weghuber, D. (2025) · Journal für Endokrinologie Diabetologie und Stoffwechsel · doi:10.1007/s41969-025-00271-9
Cutting the weight, restoring the breath: bariatric surgery in obesity hypoventilation syndrome
Nowalk, N. C., Arellano-Maric, M. P., & Mokhlesi, B. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11830
Minnetti, M., Piciocchi, C., Frigerio, F., Vincenzo, O. D., Muzzioli, L., Poggiogalle, E., Migliaccio, S., & Donini, L. M. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01653-6
Tan, H., Chen, X., Tan, X.-Y., Lv, W., Hu, T., Zhu, T., Zhao, Y., Chen, X., & Qian, B. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5360472
Effect of Sleeve Gastrectomy on Cancer Prevention
Lazzati, A. (2025) · Springer eBooks · doi:10.1007/978-3-031-77690-8_57-1
Corum, S., Morgan, T., & Thomas, A. M. (2025) · JAPhA Pharmacotherapy · doi:10.1016/j.japhar.2025.100020
Implications of the era of incretin-based weight loss therapy in menopause
Palacios, S. (2025) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2025.2540000 · Cited by 1
Vienghirun, J., Sawangjit, R., Suttiruksa, S., Chaiyakunapruk, N., Jinathongthai, P., Khunti, K. K., & Lee, S. W. H. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5372118
Langer, H. T., Gilmore, N. K., Hayden, C. M. T., Roux, J., Bariohay, B., Rhouquet, T., Awada, M., Marcotorchino, J., Bournot, L., Nunn, E. D. F., et al. (2025) · medRxiv · doi:10.1101/2025.07.28.25332295
Kozhukhov, N. D., Karpova, A. R., Sadretdinova, A. A., Kodoeva, D. G., Kardanova, A. S., Прошина, А. С., Avbakirova, A. S., Kilichev, D. R., Metov, I. S., Magomedov, L. M., et al. (2025) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2025.657 · Cited by 1
Beyond the Skinfolds: Diagnostic and Therapeutic Hope for the Obese and Formerly Obese
Miller, D. D. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.07.014
Shaw, L. J., Blankstein, R., & Chandrashekhar, Y. (2025) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2025.07.001
Cardiovascular diseases and diabetes—new focus on obesity
Dörr, R., Tschöpe, D., & Marx, N. (2025) · Herz · doi:10.1007/s00059-025-05320-2
Adipositas und Herz: neue Medikamente und neue Strategien für Kardiologen
Hollstein, T. (2025) · Aktuelle Kardiologie · doi:10.1055/a-2606-7020
Growing evidence for semaglutide efficacy in Asian adults with obesity
Sumithran, P., & Baur, L. A. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00201-3
Lytvyak, E., Grunvald, E. L., Shreekumar, D., Rye, P., Troshyn, O., Cawsey, S., Montaño‐Loza, A. J., Sharma, A. M., & Modi, R. (2025) · Obesities · doi:10.3390/obesities5030063
Oettinger, V., Mühlen, C. V. Z., Kaier, K., Wolf, D., Rilinger, J., Maier, A., Jäckel, M., Westermann, D., Hilgendorf, I., & Bockelmann, D. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02735-z
Safety analysis of tirzepatide in clinical practice
Shnaider, K. O., Kondrakhin, A. P., Maksimov, М. L., Balashova, E. P., Beschetnov, I. D., Akhmadieva, A. A., & Martynova, S. A. (2025) · Glavvrač (Chief Medical Officer) · doi:10.33920/med-03-2508-03
Conrad, M. (2024) · The Conversation · doi:10.64628/aai.xeqxva47a
Damman, C. J. (2024) · The Conversation · doi:10.64628/aai.fjd6n4h7t
Refaeli, R., Green, G., Boaz, M., Dotan, I., Raziel, A., Peffer-Gik, T., Buch, A., & Dagan, S. S. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01887-2 · Cited by 2
Kanazawa, K., Hayashi, K., Cao, X., Hijikata, M., & Kuwabara, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70062
EBM BLS: Tirzepatide Helps Obese Patients Lose Weight
Ortega, H., & BURKE, H. B. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09815-w
Incretins for obesity: closer to a nicotine patch than a silver bullet
Dippel, I., Adelman, M., Olson, K. M., Holt, A., Collins, J., Reddest, A., & Carris, N. W. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2557458
Collazo–Clavell, M. L. (2025) · New England Journal of Medicine · doi:10.1056/nejme2510196
Pharmacological targets in obesity
Pavli, P., Mastorakos, G. P., & Valsamakis, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00013-5
Tirzepatide drives weight loss in people with obesity due to MC4R deficiency
(2025) · Nature Medicine · doi:10.1038/s41591-025-03915-0
Dionisi, T., Vita, V. D., Sario, G. D., Mori, L. D., Gasbarrini, A., Gasbarrini, G., & Addolorato, G. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08193-w · Cited by 3
Effects of Endoscopic Sleeve Gastroplasty on Body Composition and Metabolism: An InBody Analysis
Lahooti, A., Gouda, Z., Rangwani, S. M., Johnson, K. E., Zureikat, Q. A., Aneke-Nash, C. S., Adejumo, A., Baig, M. U., Gay, D., Buckholz, A. P., et al. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08194-9
The essential role of the physiotherapy profession in incretin-based weight loss
Sampford, J., Myers-Ingram, R., Jones, G., & Cork, S. C. (2025) · Physiotherapy · doi:10.1016/j.physio.2025.101840
Skorupski, B. M., Nowak, D., Gradek, A., Sawczuk, M., Noskowicz, J., Urban, J., Konat, J., Długosz, P., Gryc, A., & Spitaleri, M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3678
Prediabetes in metabolic syndrome
Babenko, A. Y. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6538 · Cited by 1
Weekly Journal Scan: REDEFINing the next generation of obesity pharmacotherapy
Liuzzo, G., & Patrono, C. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf628
The New American Addiction: How Weight-Loss Drugs Could Create the Next Epidemic
Fredrick, P. (2025) · Journal of Sports Medicine and Therapy · doi:10.29328/journal.jsmt.1001096
INNOVATIONS IN OBESITY TREATMENT – GLP – 1 PHARMACOTHERAPY AND BARIATRIC SURGERY
Bartnik, P., Palmi, J., Bebrysz, E., Dębek-Kalinowska, K., Baran, J., Dunder, I., Koss, M., Biszewski, M., Drabik, A., & Ziomek, W. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3682
GLP-1 ANALOGUES IN OBESITY THERAPY: CURRENT EVIDENCE AND FUTURE DIRECTIONS – A SYSTEMATIC REVIEW
Strumnik, N., Skorupski, B. M., Sójkowska-Sławińska, O., Leśniewska, A., Macuk, P., Gniedziejko, M., Roszak, J., Bernecka, P., Hamouta, J., & Doroszuk, W. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3723
Burr, E. F., Roytman, M., Poirier, É., Kolbuszewska, M. T., Pfaus, J. G., Komisaruk, B. R., Goldstein, I., & Rubin, R. S. (2025) · Sexual Medicine · doi:10.1093/sexmed/qfaf073 · Cited by 3
Khalil, A. A. F., Kim, A. J., Cheskin, L. J., Rajagopal, S., Morefield, B., Chaudhry, Z. W., Gudzune, K. A., & Weiss, C. R. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100211
Sex Differences in Cardiovascular-Related Responses to Obesity Treatment
Silver, N., Ghanta, A., Abene, J., Pinto, Y., & Chao, A. M. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00774-9
Hsu, K. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70163
Vahedi, F., Yalamanchi, M., & Issa, D. (2025) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000001134
Effect of Tirzepatide on Cardiovascular Outcomes
Huston, J., Orey, D., Ashchi, A., Lachapelle, A. A., Genovese, A., Jackson, J., Ashchi, R., Ashchi, T., Ashchi, M., Sutton, D., et al. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00767-4 · Cited by 1
Obesity and hypertension new insights in management
Catalfamo, V. J., Koos, A., Tutor, A. W., & Lavie, C. J. (2025) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001261
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Hernández, A. R., Araujo, J. E. G., Castillo, J. F. D., Martínez, M. E. A., Cohen, N. E. Z., Navarro, A. F. U., Chavez, M. A. N., & Morales, A. L. L. (2025) · Star of Sciences Multidisciplinary Journal · doi:10.63969/tg610p62
Obesity: a disease of the ponderostat and the regulation of energy balance
Buscemi, S., Buscemi, C., Colombrita, P., Randazzo, C., Barile, A. M., & Arnaldi, G. (2025) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-025-01790-9 · Cited by 2
Bruinsma, F. F. E., van Schuppen, S., Liem, R. S. L., de Mheen, P. J. M., & Nienhuijs, S. W. (2025) · Obesity Surgery · doi:10.1007/s11695-025-08284-8
de Souza, L. A. G., Brim, A. D. A., Filho, A. C. C. D. S., Freire, M. D. S., de Souza, R. A. G., & Peixoto, M. C. (2025) · RCMOS - Revista Científica Multidisciplinar O Saber · doi:10.51473/rcmos.v1i2.2025.1548 · Cited by 2
Efficacy of Mazdutide in Nondiabetic Adults with Overweight or Obesity: A Meta-AnalysisPreprint
Yassin, M. N. A., Sayed, M. S., Saad, O. A., Hussein, Z. A., & Abouelmagd, A. A. (2025) · Research Square · doi:10.21203/rs.3.rs-7884657/v1
Vicarious efficacy of tirzepatide in a cohabiting couple: An observational case report
Eason, K., Feeney, C., & Killeen, T. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100219
The role of Lifestyle Medicine in obesity management: a complementary approach
Agusala, B., & Clark, J. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01937-9
Tirzepatide vs. Semaglutide for Obesity Treatment
Muskiet, M. H. A., Winter, E. M., & Rensen, P. C. N. (2025) · New England Journal of Medicine · doi:10.1056/nejmc2510962
Coleman, M. F., McDonell, S. B., Eisenbeis, L. K., Devericks, E. N., Chandi, J., Dave, O., Pearce, J. B., Wang, S., Cody, M., Bustamante-Marin, X. M., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-025-02134-2
EFFECTIVENESS OF SEMAGLUTIDE IN OBESITY TREATMENT AND THE ROLE OF LIFESTYLE INTERVENTIONS
Bracichowicz, F., Winogrodzki, I., Kowalczyk, P., Paszkiewicz, H., Nowak, K., Gęsińska, A., Stryczek-Schlusche, A., Trzciński, B., Gugała, O., & Furczyńska, A. M. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(47).2025.3931
The importance of science communication surrounding weight-loss drugs
Yeo, G. S. H. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00320-1
Efficacy and Safety of Tirzepatide in Refractory Hypoglycemia Associated with Esophagojejunostomy
Caporusso, M., Gioia, L. D., Manicone, M., Matera, L., Giorgino, F., & Perrini, S. (2025) · JCEM Case Reports · doi:10.1210/jcemcr/luaf249
Weight Management Experiences Among People With CKD: A Qualitative Study
Noori, M., Brahmbhatt, R., Clemens, K. K., & MOIST, L. M. (2025) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581251380499 · Cited by 1
Wilkins, F. L., Moore, W. S., Jackson, J. R., & McVay, M. A. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251392887
Yagnik, V. D., & Choudhary, P. R. (2025) · Journal of Gastrointestinal Surgery · doi:10.1016/j.gassur.2025.102276
Tratamiento de la angina estable
Álvarez, B. Á., Martínez, J. M., Bermejo, R. M. A., Álvarez, D. I., Veloso, P. R., García‐Acuña, J. M., & González‐Juanatey, J. R. (2025) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2025.10.003
Selective amylin receptor agonism: promise beyond incretins
van Beek, A. P. (2025) · The Lancet · doi:10.1016/s0140-6736(25)02214-7
GLP-1 Receptor Agonists: Advances in Mechanism, Therapeutic Applications, and Future Perspectives
Pawar, M., Patil, C. S., Fakir, J. S., Pagar, D. S., & Mahajan, S. K. (2025) · BioMed Target Journal · doi:10.59786/bmtj.322 · Cited by 1
Pontiroli, A. E., Guarino, S., Tagliabue, M., Sala, L. L., Centofanti, L., Olmi, S., Sarro, G., Giovanelli, A., Asteria, C., Galfrascoli, E., et al. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02604-1
Xiao, Y., Chen, J., Guo, M., Liu, X., Xu, X.-M., Yan-qun, L., Jiang, Z., Xu, Y., & Deng, C. (2025) · Research Square · doi:10.21203/rs.3.rs-7103001/v1 · Cited by 1
SAÚDE MENTAL NO EMAGRECIMENTO: EFEITOS ADVERSOS DE NOVAS TERAPIAS FARMACOLÓGICAS
de Macedo, K. M. A., & Rodrigues, O. M. (2025) · Revista Foco · doi:10.54751/revistafoco.v18n11-117
Medications for the Management of Obesity
Giruzzi, N. R. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch29
Kolaczynski, J. W., & Surmacz, E. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101449
Emanuelsson, E. B., & Horwath, O. (2025) · The Journal of Physiology · doi:10.1113/jp290350
Cunningham, J. M., Nolan, E., & Palacio, C. (2025) · Journal of General Internal Medicine · doi:10.1007/s11606-025-09988-4
GLP-1-Rezeptor-Agonisten bei Bluthochdruck und Übergewicht
Babic, M., & van der Giet, M. (2025) · Die Nephrologie · doi:10.1007/s11560-025-00887-7
Metadata
- Authors
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A.
- Affiliations
- Eli Lilly (United States) (US)
- From the Section of Endocrinology and Metabolism, Department of Medicine, and the Section of Pediatric Endocrinology, Department of Pediatrics, Yale University School of Medicine, New Haven, CT (A.M.J.); the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine, New York (L.J.A.); Eli Lilly, Indianapolis (N.N.A., S.Z., B.L., M.C.B., A.S.); McMaster University, Hamilton, and York University and Wharton Weight Management Clinic, Toronto — all in Ontario, Canada (S.W.); Intend Research, Norman, OK (L.C.); Centro Paulista De Investigação Clínica (Cepic), Sao Paulo (B.A.); and Tokyo-Eki Center-Building Clinic, Tokyo (A.K.).
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-07-21
- Volume
- 387
- Issue
- 3
- Pages
- 205-216
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W4281934192
- Semantic Scholar
- 3fb03384cc726ebd9d08c76482e6edf35502d0c7
- Cited by
- 3,838
- References
- 28
- Citations by year
- 2026: 1279 · 2025: 1067 · 2024: 776 · 2023: 562 · 2022: 149
- FWCI
- 382.29
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- tirzepatide, obesity, weight loss, GLP-1 receptor agonists, GIP receptor agonist, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, dose escalation, body mass index, weight-related comorbidities, treatment discontinuation, treatment-emergent adverse events, drug safety, subcutaneous administration
- MeSH terms
- Tirzepatide, Adult, Dose-Response Relationship, Drug, Double-Blind Method, Glucagon-Like Peptides, Gastric Inhibitory Polypeptide, Humans, Injections, Subcutaneous, Obesity, Weight Loss, Treatment Outcome, Anti-Obesity Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.